Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:56 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 13,733 matching trials from the live ClinicalTrials.gov search.
Filters: Baltimore, Maryland Clear all
Completed No phase listed Observational

Global Patient Registry of Inherited Retinal Diseases

NCT05957276
View directory record Official record
Conditions
Inherited Retinal Diseases
Interventions
Standard of Care
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
886 participants
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 3 Interventional

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00080340
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
270
States / cities
Birmingham, Alabama • Glendale, Arizona • Benton, Arkansas + 174 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Nov 2, 2026, 5:56 PM EST
Active, not recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Recruiting Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

NCT06654752
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 18 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 2, 2026, 5:56 PM EST
Terminated Phase 2 Interventional

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

NCT06322576
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
177Lu-PNT2002
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed Not applicable Interventional

Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

NCT00670917
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Pain
Interventions
questionnaire administration, acupressure therapy, biopsy, bone marrow aspiration, pain therapy
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Duration of Effect of Acidform Gel on Vaginal pH

NCT02693418
View directory record Official record
Conditions
Healthy
Interventions
Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 1 Interventional

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

NCT00215709
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Nov 2, 2026, 5:56 PM EST
Recruiting Phase 3 Interventional

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia
Interventions
mocravimod
Drug
Lead sponsor
Priothera SAS
Industry
Eligibility
18 Years to 75 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Nov 2, 2026, 5:56 PM EST
Terminated Phase 4 Interventional Results available

NSAIDs vs. Coxibs in the Presence of Aspirin

NCT03699293
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases
Interventions
celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet
Drug
Lead sponsor
Platelet and Thrombosis Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed No phase listed Observational Results available

The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

NCT03165526
View directory record Official record
Conditions
Post-Infarction Ventricular Septal Defect
Interventions
AMPLATZER™ Post-infarct Muscular VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 2, 2026, 5:56 PM EST
Terminated Phase 3 Interventional

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

NCT02562443
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 2, 2026, 5:56 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Single and Multiple Dose of HL-400

NCT06997484
View directory record Official record
Conditions
Parkinson Disease
Interventions
HL-400, Placebo
Drug
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed No phase listed Observational

MAVRIC VR ICD Registry

NCT00270933
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Fibrillation
Interventions
Registry
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
81
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 2, 2026, 5:56 PM EST
Active, not recruiting Phase 2 Interventional

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 2, 2026, 5:56 PM EST
Withdrawn Not applicable Interventional

Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination

NCT01493258
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
iCOPE Intervention group
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Nov 2, 2026, 5:56 PM EST
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 2, 2026, 5:56 PM EST
Completed No phase listed Observational

Automatic Versus Evaluative Components of Cue Reactivity

NCT01036126
View directory record Official record
Conditions
Drug Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 5:56 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

NCT02262689
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 2, 2026, 5:56 PM EST
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
304
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 5:56 PM EST